Who are Ribavirin, PEG-Intron's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Paxlovid (Copackaged), Lonsurf, PODOFILOX, Dendrid, D+Z, Pegasys&Entecavir.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ribavirin-peg-intron.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Ribavirin, PEG-Intron — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Ribavirin, PEG-Intron (Ribavirin, PEG-Intron) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antiviral. Area: Infectious Diseases.

phase 3 Antiviral Infectious Diseases Small molecule Live · refreshed every 30 min

Target snapshot

Ribavirin, PEG-Intron (Ribavirin, PEG-Intron) — Weill Medical College of Cornell University. Ribavirin is an antiviral medication that works by inhibiting viral RNA synthesis, while PEG-Intron is an interferon that stimulates the body's immune response to fight viral infections.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Ribavirin, PEG-Intron TARGET	Ribavirin, PEG-Intron	Weill Medical College of Cornell University	phase 3	Antiviral
Paxlovid (Copackaged)	Nirmatrelvir	Pfizer	marketed	Antiviral protease inhibitor	SARS-CoV-2 main protease (Mpro, 3CLpro, nsp5 protease)	2023-01-01
Lonsurf	TIPIRACIL	Taiho Oncology Inc	marketed	Nucleoside Analog Antiviral [EPC]	Thymidine phosphorylase	2015-01-01
PODOFILOX	PODOFILOX		marketed	Topical antiviral	Unknown	1990-01-01
Dendrid	IDOXURIDINE	Novartis	marketed	Nucleoside Analog Antiviral	Thymidine kinase, cytosolic	1963-01-01
D+Z	D+Z	Sequential Medicine Ltd	marketed	Direct-acting antiviral (DAA) combination	HCV NS5A protein and HCV NS5B RNA-dependent RNA polymerase
Pegasys&Entecavir	Pegasys&Entecavir	National Taiwan University Hospital	marketed	Combination antiviral therapy (interferon + nucleoside reverse transcriptase inhibitor)	Hepatitis B virus polymerase; interferon-alpha receptor signaling

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2029-09-22 — Lonsurf · RE46284 · US
2034-06-17 — Lonsurf · 10457666 · US
2034-06-17 — Lonsurf · 9527833 · US
2034-09-05 — Lonsurf · 9943537 · US
2037-02-03 — Lonsurf · 10456399 · US
2037-02-03 — Lonsurf · 10960004 · US
2041-08-05 — Paxlovid (Copackaged) · 11351149 · US
2041-10-31 — Paxlovid (Copackaged) · 11541034 · US

Sponsor landscape (Antiviral class)

Ain Shams University · 1 drug in this class
Arbutus Biopharma Corporation · 1 drug in this class
Australasian Gastro-Intestinal Trials Group · 1 drug in this class
Casa Sollievo della Sofferenza IRCCS · 1 drug in this class
Hospital Universitari Vall d'Hebron Research Institute · 1 drug in this class
Invivyd, Inc. · 1 drug in this class
JW Pharmaceutical · 1 drug in this class
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · 1 drug in this class
Pfizer · 1 drug in this class
Professor Francois Venter · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Ribavirin, PEG-Intron — Competitive Intelligence Brief. https://druglandscape.com/ci/ribavirin-peg-intron. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing